Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial

Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。